Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cytokinetics
(NASDAQ:CYTK)
Intraday
$63.61
-1.19
[-1.84%]
After-Hours
$63.61
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$63.61
-1.19
[-1.84%]
At close: Apr 26
$63.61
0
[0.00%]
After Hours: 7:56PM EDT
Get Report
Watch
Q1 2024 Earnings in 10 days from now on Wed May 8th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Cytokinetics Stock (NASDAQ:CYTK)
Cytokinetics Stock (NASDAQ: CYTK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 26, 2024
On April 23, Cytokinetics Entered Employment Offer Letter With Sung H. Lee, Pursuant To Which, Lee Agreed To Serve As Executive Vice President, CFO
Benzinga Newsdesk
-
2 days ago
Wednesday, April 10, 2024
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
Benzinga Newsdesk
-
Apr 10, 2024, 7:31AM
Tuesday, April 09, 2024
Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 5:54AM
Monday, April 08, 2024
Truist Securities Reiterates Buy on Cytokinetics, Maintains $86 Price Target
Benzinga Newsdesk
-
Apr 8, 2024, 11:07AM
Friday, April 05, 2024
Cytokinetics shares are trading higher after the company announced additional 48-week data from its FOREST-HCM to be presented at the Annual American College of Cardiology Scientific Session Apr. 6-8.
Benzinga Newsdesk
-
Apr 5, 2024, 2:38PM
Cytokinetics Says It Presented Additional 48-Week Data From FOREST-HCM, The Open Label Extension Clinical Study of Aficamten, At The American College Of Cardiology 73ʳᵈ Annual Scientific Session
Benzinga Newsdesk
-
Apr 5, 2024, 7:32AM
Wednesday, April 03, 2024
$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today
Benzinga Insights
-
Apr 3, 2024, 2:00PM
Tuesday, March 26, 2024
This Is What Whales Are Betting On Cytokinetics
Benzinga Insights
-
Mar 26, 2024, 4:15PM
Friday, March 15, 2024
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Benzinga Insights
-
Mar 15, 2024, 11:00AM
Thursday, March 07, 2024
JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $77
Benzinga Newsdesk
-
Mar 7, 2024, 2:16PM
Wednesday, March 06, 2024
Mizuho Maintains Buy on Cytokinetics, Lowers Price Target to $99
Benzinga Newsdesk
-
Mar 6, 2024, 8:12AM
Monday, March 04, 2024
Oppenheimer Reiterates Outperform on Cytokinetics, Maintains $107 Price Target
Benzinga Newsdesk
-
Mar 4, 2024, 8:45AM
Wednesday, February 28, 2024
Cytokinetics shares are trading lower after the company reported worse-than-expected Q4 financial results.
Benzinga Newsdesk
-
Feb 28, 2024, 2:31PM
Unpacking the Latest Options Trading Trends in Cytokinetics
Benzinga Insights
-
Feb 28, 2024, 1:45PM
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $94 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 1:16PM
Needham Reiterates Buy on Cytokinetics, Maintains $108 Price Target
Benzinga Newsdesk
-
Feb 28, 2024, 5:39AM
Tuesday, February 27, 2024
Cytokinetics Anticipates 2024 Revenue Of $3M-$5M; Approximately 2 Years Of Cash Runway
Benzinga Newsdesk
-
Feb 27, 2024, 5:49PM
Cytokinetics Q4 2023 GAAP EPS $(1.38) Misses $(0.97) Estimate, Sales $1.67M Miss $10.77M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 4:10PM
Here's How Much $1000 Invested In Cytokinetics 10 Years Ago Would Be Worth Today
Benzinga Insights
-
Feb 27, 2024, 1:30PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Tuesday, February 13, 2024
Cytokinetics CEO Says "We Have Not Been Conducting A For Sale Process For Cytokinetics. But When People Knock On Our Door, We Have A Fiduciary Obligation To Open The Door And Address And Engage"
Benzinga Newsdesk
-
Feb 13, 2024, 11:18AM
Cytokinetics Now Presenting At Oppenheimer 34th Annual Healthcare Life Sciences Conference; Shares See Volume
Benzinga Newsdesk
-
Feb 13, 2024, 11:15AM
Friday, February 09, 2024
Here's How Much $1000 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Benzinga Insights
-
Feb 9, 2024, 3:00PM
Monday, February 05, 2024
Banco Santander, Lloyds Banking And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
-
Feb 5, 2024, 5:21AM
Friday, February 02, 2024
Here's How Much $100 Invested In Cytokinetics 5 Years Ago Would Be Worth Today
Benzinga Insights
-
Feb 2, 2024, 2:00PM
Monday, January 29, 2024
This Is What Whales Are Betting On Cytokinetics
Benzinga Insights
-
Jan 29, 2024, 12:30PM
Thursday, January 25, 2024
Cytokinetics Says It Presented New Data At CMR 2024 From FOREST-HCM, The Open Label Extension Clinical Trial Of Aficamten
Benzinga Newsdesk
-
Jan 25, 2024, 7:36AM
Wednesday, January 24, 2024
UBS Downgrades Cytokinetics to Neutral, Raises Price Target to $92
Benzinga Newsdesk
-
Jan 24, 2024, 7:57AM
Tuesday, January 23, 2024
Cytokinetics Unusual Options Activity For January 23
Benzinga Insights
-
Jan 23, 2024, 1:16PM
Monday, January 22, 2024
Mizuho Maintains Buy on Cytokinetics, Raises Price Target to $103
Benzinga Newsdesk
-
Jan 22, 2024, 9:17AM
Thursday, January 18, 2024
Cytokinetics Announces New Data From FOREST-HCM To Be Presented At CMR 2024
Benzinga Newsdesk
-
Jan 18, 2024, 1:00PM
Monday, January 15, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
-
Jan 15, 2024, 12:35PM
Friday, January 12, 2024
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
Vandana Singh
-
Jan 12, 2024, 2:38PM
Cytokinetics's Options Frenzy: What You Need to Know
Benzinga Insights
-
Jan 12, 2024, 9:46AM
Thursday, January 11, 2024
Cytokinetics shares are trading lower following a report suggesting Novartis has backed away from a potential deal for the company.
Benzinga Newsdesk
-
Jan 11, 2024, 3:17PM
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
Vandana Singh
-
Jan 11, 2024, 2:22PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jan 11, 2024, 12:31PM
"Novartis Pursuit Of Cytokinetics Cools; Swiss Drug Maker Had Been Expected To Clinch Deal For Heart-drug Developer As Soon As This Week" - WSJ
Benzinga Newsdesk
-
Jan 11, 2024, 12:22PM
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
Avi Kapoor
-
Jan 11, 2024, 10:32AM
Tuesday, January 09, 2024
What's Been Happening With Cytokinetics Stock?
Ryan Gustafson
-
Jan 9, 2024, 3:42PM
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Jan 9, 2024, 12:35PM
Monday, January 08, 2024
Why Is Heart Failure Drug-Focused Cytokinetic Stock Trading Higher Today?
Vandana Singh
-
Jan 8, 2024, 2:24PM
Market Whales and Their Recent Bets on CYTK Options
Benzinga Insights
-
Jan 8, 2024, 2:00PM
Cytokinetics shares are trading higher following a report suggesting Novartis is in advanced talks to buy the company.
Benzinga Newsdesk
-
Jan 8, 2024, 1:07PM
"Novartis In Advanced Talks To Buy Cytokinetics; Acquisition Would Be Latest In A Flurry Of Deals By Pharmaceutical Giants For Hot Biotechs" - WSJ
Benzinga Newsdesk
-
Jan 8, 2024, 12:58PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Jan 8, 2024, 8:05AM
Friday, January 05, 2024
This Is What Whales Are Betting On Cytokinetics
Benzinga Insights
-
Jan 5, 2024, 3:46PM
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
-
Jan 5, 2024, 8:23AM
Morgan Stanley Downgrades Cytokinetics to Equal-Weight, Raises Price Target to $90
Benzinga Newsdesk
-
Jan 5, 2024, 6:12AM
Thursday, January 04, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Jan 4, 2024, 12:35PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch